2-(4-甲砜基苯基)乙胺 | 153402-45-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-甲砜基苯基)乙胺
• 英文名称: 2-(4-methylsulfonyl-phenyl)ethylaminehydrochloride
• 英文别名: 2-(4-methylsulfonylphenyl)ethan-1-amine；2-(4-methylsulfonylphenyl)ethanamine；4-methanesulfonylphenylethylamine；4-Mesylphenylethylamine；4-methanesulfonyl-phenethylamine；4-Methansulfonyl-phenaethylamin；2-[4-(Methylsulfonyl)phenyl]ethylamine
• CAS: 153402-45-0
• 化学式: C₉H₁₃NO₂S
• mdl: MFCD08449042
• 分子量: 199.274
• InChiKey: XFXSJOHJDZJFCP-UHFFFAOYSA-N

物化性质

• 沸点：
  377.1±34.0 °C(Predicted)
• 密度：
  1.188±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-甲砜基苯基)乙胺 在 四(三苯基膦)钯 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 异丙醇 为溶剂， 反应 20.0h， 生成 tert-butyl 4-(2-amino-6-{[2-(4-methanesulfonylphenyl)ethyl]amino}pyrimidin-4-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate
  参考文献：
  名称：

  [EN] MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS
  [FR] INHIBITEURS DE MTH1 DESTINÉS AU TRAITEMENT DES ÉTATS INFLAMMATOIRES ET AUTO-IMMUNS

  摘要：

  化合物的化学式（I），或其药学上可接受的盐，用于治疗自身免疫性疾病和炎症性疾病。

  公开号：

  WO2015187089A1
• 作为产物：
  描述：

  2-(4-(甲基硫代)苯基)乙胺 在 sodium hydroxide 吡啶 作用下， 以 水 为溶剂， 反应 25.0h， 生成 2-(4-甲砜基苯基)乙胺
  参考文献：
  名称：

  Physicochemical factors affecting the uptake by roots and translocation to shoots of amine bases in barley

  摘要：

  The uptake by barley roots from nutrient solution and subsequent transport to shoots of two series of amine bases were measured over 6 to 72 h. The compounds were chosen to span systematically ranges of lipophilicity (assessed using 1-octanol/water partition coefficients, K-ow) and pKa that would include commercial pesticide amines. In a series of six substituted phenethylamines, strong bases with pKa similar to 9.5, all the compounds were strongly taken up by roots from solutions of pH 8.0; uptake declined substantially as the pH was lowered to 5.0, especially for the compounds of intermediate lipophilicity (log k(ow) 2 to 3). This uptake could be ascribed to three processes: (i) accumulation of the cation inside the root cells due to the negative charge on the plasmalemma, as given by the Nernst equation and important only for the polar compounds which have low permeation rates through membranes; (ii) accumulation into the vacuole by ion-trapping, which was the dominant process at high pH for all compounds and at all pH values for the compounds of intermediate lipophilicity; (iii) partitioning on to the root solids, substantial only for the most lipophilic compounds. Translocation to shoots was proportional to uptake by roots, this ratio being independent of external pH for each compound and being optimal for the compounds of intermediate lipophilicity. Such proportionality was also observed in a series of three weaker bases of intermediate lipophilicity, in which compounds of pKa 7.4 to 8.0 were also well taken up and translocated whereas the very weak base 4-ethylaniline (pKa 5.03) was much less so. Tests with quaternised pyridines confirmed that organic cations move only slowly through membranes. The observed behaviour of the amines could be modelled reasonably well assuming that transport within the plant was dominated by movement across membranes of the non-ionised species, and this appeared to be true even for the most lipophilic phenethylamine (log K-ow 4.67) studied, though its long-distance movement would be as the protonated species. (C) 1998 Society of Chemical Industry.

  DOI：

  10.1002/(sici)1096-9063(199809)54:1<8::aid-ps793>3.0.co;2-e

文献信息

• HIV INTEGRASE INHIBITORS
  申请人：ViiV Healthcare Company

  公开号：US20150225399A1

  公开（公告）日：2015-08-13

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明具有作为HIV整合酶抑制剂的化合物，因此在抑制HIV复制、预防及/或治疗HIV感染以及治疗艾滋病及/或艾滋病相关综合症方面具有用途。
• [EN] MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS<br/>[FR] INHIBITEURS DE MTH1 DESTINÉS AU TRAITEMENT DES ÉTATS INFLAMMATOIRES ET AUTO-IMMUNS
  申请人：THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING

  公开号：WO2015187089A1

  公开（公告）日：2015-12-10

  A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.

  化合物的化学式（I），或其药学上可接受的盐，用于治疗自身免疫性疾病和炎症性疾病。
• 一种大环内酯类化合物
  申请人：普莱柯生物工程股份有限公司

  公开号：CN105669798B

  公开（公告）日：2019-07-26

  本发明涉及一种如式Ⅰ所示的大环内酯类化合物及其药学上可接受的盐。本发明所述化合物是抗菌剂，可用于治疗各种细菌和原生动物感染。本发明还涉及所述化合物的制备方法及其药物组合物，
• [EN] PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRIMIDINE-2,4-DIAMINE UTILISABLES EN VUE DU TRAITEMENT DU CANCER
  申请人：THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING

  公开号：WO2014084778A1

  公开（公告）日：2014-06-05

  A compound of formula (I), or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.

  公式(I)的化合物，或其药用可接受的盐。该化合物可用于治疗癌症或其他可能从抑制MTH1中受益的疾病。
• [EN] COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DU RÉCEPTEUR A2B DE L'ADÉNOSINE ET DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：CORVUS PHARMACEUTICALS INC

  公开号：WO2019046784A1

  公开（公告）日：2019-03-07

  Disclosed herein, inter alia, are compositions and methods for modulating Adenosine Receptors. In an aspect is provided a method of inhibiting Adenosine A2B Receptor activity and Adenosine A2A Receptor activity, the method including contacting the Adenosine A2B Receptor and Adenosine A2A Receptor with a compound as described herein, including embodiments.

  在此披露的内容包括调节腺苷受体的组合物和方法。在一个方面，提供了一种抑制腺苷A2B受体活性和腺苷A2A受体活性的方法，该方法包括将腺苷A2B受体和腺苷A2A受体与本文描述的化合物接触，包括各种实施方式。